NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 198 filers reported holding NOVOCURE LTD in Q2 2019. The put-call ratio across all filers is 0.51 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $1,480,000 | -64.9% | 12,741 | -33.0% | 0.19% | -29.1% |
| Q2 2021 | $4,216,000 | +261.6% | 19,008 | +37.3% | 0.27% | +3.5% |
| Q1 2020 | $1,166,000 | -50.0% | 13,840 | -50.0% | 0.26% | -42.2% |
| Q4 2019 | $2,332,000 | +137.5% | 27,680 | +110.8% | 0.45% | +4.9% |
| Q3 2019 | $982,000 | -25.8% | 13,133 | -37.3% | 0.43% | -22.8% |
| Q2 2019 | $1,324,000 | +0.4% | 20,936 | -23.6% | 0.55% | +17.2% |
| Q1 2019 | $1,319,000 | – | 27,391 | – | 0.47% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Nordwand Advisors, LLC | 1,515,000 | $111,125,249 | 13.86% |
| Invus Financial Advisors, LLC | 350,884 | $25,737,341 | 13.70% |
| HARTLINE INVESTMENT CORP/ | 304,482 | $22,333,755 | 5.08% |
| GREAT POINT PARTNERS LLC | 241,000 | $17,677,350 | 3.46% |
| Tri Locum Partners LP | 72,400 | $5,311,000 | 2.15% |
| Taylor Frigon Capital Management LLC | 42,061 | $3,085,174 | 1.75% |
| HighVista Strategies LLC | 28,007 | $2,054,313 | 1.22% |
| HAP Trading, LLC | 124,500 | $10,294 | 1.05% |
| Private Harbour Investment Management & Counsel, LLC | 12,285 | $901,105 | 0.99% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 32,000 | $2,344,000 | 0.72% |